Although not associated with PCa, COL4A2 loss has been identified to inhibit triple-negative breast cancer cell proliferation and migration74 and its mutations as a risk factor for familial cerebrovascular disease75, while inactivation of SLC2A5 has been found to inhibit cell proliferation and migration in multiple cancer cell lines76. Here, SLC2A5 is linked to triple-negative breast carcinoma.